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Abstract Tissue inhibitors of metalloproteinase (TIMPs) are 
inhibitory counterparts of collagenases, containing 12 cysteine 
residues paired to six internal disulphide bridges. TIMP-2, an 
inhibitory protein of 72 kDa gelatinase/type IV collagenase 
(MMP-2), was expressed in Escherichia coli as a fusion protein 
with a 34 amino acid NH2-1inked tail containing six consecutive 
histidine residues. The protein was purified in a single-step using 
an ion metal affinity column (IMAC) in denaturing conditions. 
The immobilized fusion TIMP-2 protein was refolded at a high 
concentration in the column, producing about 5 mg of protein per 
litre of bacterial cells. It shows specific binding and inhibitory 
activity against MMP-2, but has no effect against 92 and 45 kDa 
gelatinases. 
Key words." Tissue inhibitor of metalloproteinase; Type IV 
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I. Introduction 
TIMP-2, the second member of the family of tissue inhibitors 
of matrix metalloproteinases (MMPs) [1 3] is a non-glycosyl- 
ated 21 kDa protein which exerts activity against several mem- 
bers of the MMP family, although preferentially toward the 72 
kDa gelatinase/type IV collagenase (MMP-2 or gelatinase A), 
by binding to both its latent and activated forms [4,5]. MMP-2 
expression has been repeatedly correlated to invasive and 
metastatic aggressiveness of tumour cells, and TIMP-2 inhibits 
matrix invasion by transformed cells [6] and endothelial cell 
proliferation [7] in vitro, as well as metastasis n vivo [8]. Nev- 
ertheless, deeper comprehension f proteinase-inhibitor inter- 
actions is still crucial for designing and checking pharmacologi- 
cal strategies for controlling pathological matrix proteolysis. 
Although the availability of TIMP-2 active protein from natu- 
ral sources poses a serious limitation in this respect, DNA 
recombinant technology may help. 
TIMP-1, the first cloned member of the tissue inhibitor fam- 
ily, has been produced more or less successfully by recombinant 
techniques using mammalian cells [9], E. coli [10-13] or bacu- 
lovirus systems [14,15]. The second member, TIMP-2, was later 
produced only using mammalian cell systems [16-18]. 
Although DNA technology now permits burst synthesis of 
heterologous proteins in E. coli, these often accumulate as in- 
soluble inclusion bodies, and denaturatio~renaturation sys- 
tems are necessary to obtain the native conformation [19]. 
Protein renaturation is not a simple process, above all when 
large and complex molecules are involved. The main problem 
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is usually protein insolubility, as a consequence of the aggrega- 
tion of incorrectly folded molecules, which in turn may be due 
to the presence of incorrect disulphide bridges. For this reason, 
most refolding systems involve dilution of denatured proteins 
to -< 10/,tM in an appropriate folding buffer. Several strategies 
have been developed to obtain renaturation of proteins in the 
presence of redox agents uch as glutathione, fl-mercaptoetha- 
nol, metal ions, denaturing agents, etc. Although a number of 
these systems do produce good results in some protein models, 
due to the multiple chemical~hysical properties characteristic 
of each protein, yield is often poor and more appropriate re- 
folding must be tailored. 
We tackled this need in T1MP-2, which contains 12 cysteine 
residues linked through 6 disulphide bridges. Fused to a NH2- 
tail of 34 amino acids, TIMP-2, was highly expressed in E. eoli, 
the chimeric protein was isolated by affinity chromatography 
specific for the tail, and refolding was obtained with the protein 
still linked to the resin. The refolded recombinant fusion pro- 
tein retains its specific binding and inhibitory activity for 72 
kDa gelatinase/type IV collagenase. 
2. Materials and methods 
2.1. Materials 
Restriction endonuclease and T4 DNA ligase were purchased from 
Gibco-BRL. Deoxyoligonucleotide primers were synthesized using 
phosphoramitide ch mistry and an Applied Biosystem 380B automated 
DNA synthesizer. The polymerase chain reaction was performed using 
the Amplitaq kit (Cetus-Perkin Elmer). Plasmid pRSETA was pur- 
chased from Invitrogen. The host cell line E. coli BL21 (DE3) was 
generously provided by Dr. Stan Tabor (Harvard Medical School). 
DNA manipulation, transformation a d plasmid purification were per- 
formed according to published procedures [20]. 
2.2. Construction fpSETIMP-2 plasmid 
TIMP-2 gene from a pT2-MO1 plasmid-containing fragment [21] 
was cloned directly in pRSETB plasmid, which originated pRSETIMP- 
2 plasmid. The latter was constructed in E. eoli strain HB101 and 
sequences were verified by double-strand di eoxy sequencing [22] using 
a sequenase r agent kit (United States Biochemical). 
2.3. Synthesis and purification of recomb&ant protein 
The purified pRSETIMP-2 expression plasmid was transferred into 
E. coli BL21 (DE3) for expression of the recombinant protein. Freshly 
prepared bacterial cells bearing the plasmid were grown at 37°C in 2 
liters of Luria's Broth with 100/tg/ml ampicillin until the absorbence 
of the culture suspension reached 0.7 (590 nm). Expression of rhTIMP- 
2 was induced by adding 1 mM isopropyl-fl-o-thiogalactopyranoside to 
inactivate the lac repressor, thereby allowing synthesis of T7 RNA 
polymerase which, in turn, transcribes DNA sequences next to the T7 
promoter, with the subsequent production of the fusion protein [23]. 
Three hours after induction the bacteria were harvested by centrifuga- 
tion, washed in phosphate-buffered saline (PBS) and resuspended in
PBS. Cells were lysed by sonication (Branson Sonifer at power setting 
6) for 5 min at 4°C in 6 M guanidinium-HC1, 0.1 M NaHzPO 4 and 
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10 mM Tris-HCl (pH 8.0). The lysate was cleared by centrifugation at
12,000 x g for 20 min and then filtered through a 0.45/2m Millipore 
membrane. This filtrate was applied to an immobilized metal ion affÉn- 
ity chromatographic (IMAC) column (0.8 × 4 cm Ni2+-NTA; Diagen). 
After exhaustive washing with 8 M urea, 0.1 M NaH2PO4 and 10 mM 
Tris-HCl (pH 8.0), the recombinant protein was eluted from the IMAC 
column with 8 M urea, 0.1 M NaH2PO 4 and 10 mM Tris-HC1, using 
a pH 5.9-4.5 step gradient. 
2.4. Refolding in solution of rhTIMP-2 
IMAC-purified rhTIMP-2 (1 mg/ml) was diluted to 6 M urea and the 
pH was adjusted to 7.4. fl-mercaptoethanol was then added to a final 
concentration f 140 mM, and the solution diluted 4 times in 6 M urea, 
250 mM cystamine and 50 mM Tris-HC1 (pH 7.4). The mixture was 
further diluted to 0.3 M urea by adding 50 mM Tris-HC1 (pH 9.0), the 
final solution adjusted to pH 8.3, and kept for 24 h at 4°C. The diluted 
protein was concentrated 20times by ultrafiltration on a YM 10 Amicon 
membrane. 
2.5. Solid-phase refolding of rhTIMP-2 
Two mg of IMAC-purified rhTIMP-2 were reduced with 10 mM 
fl-mercaptoethanol and loaded once again in a 2-ml IMAC resin col- 
umn, in 100 mM Tris-HC1 (pH 8.0) with continuous recycling. The resin 
was recovered and dialysed slowly against 1 M urea (pH 8.3) and, after 
three days at 10°C, the recombinant protein was eluted from it with 
250 mM imidazole, 0.1 M NaH2PO4 and 10 mM Tris-HC1 (pH 8). The 
fusion protein was then exhaustively dialysed against TIMP-buffer 
(20 mM Tris-HC1, 200 mM NaCI, 5 mM CaC12 and 0.005% Triton 
X-100, pH 7.5). Protein concentration was determined by ultraviolet 
(UV) absorbent spectroscopy at 280 nm using a double-beam Perkin- 
Elmer spectrophotometer model Lambda-2 and 1-cm path length 
quartz cuvettes. An extinction coefficient of 0.1% (w/w) at 280 nm of 
TIMP-2 protein was taken as 1.46 mg ~.cm< Extinction coefficients 
were determined according to the method of Gill and von Hippel [24]. 
2.6. Binding of 72 kDa collagenase to rhTIMP-2 
100 fig of refolded rhTIMP-2 were incubated for 2 h at room temper- 
ature with fresh medium and medium conditioned by A2058 cells. 
Subsequently, 200/21 of IMAC resin washed in H20 were added to the 
medium, incubated for 2 h at room temperature, and packed into an 
EconoColum (BioRad). After exhaustive washing with phosphate-buff- 
ered saline (pH 7.8), the bound proteins were eluted from the column 
with 250 mM imidazole. 
2.7. Analytical SDS-polyacrylamide gel electrophoresis and Western 
blot analysis 
Polyacrylamide g l electrophoresis in the presence of sodium dodecyl 
sulphate (SDS-PAGE) was performed using an acrylamide concentra- 
tion of 5% in the stacking and 12% in the separating gel, stained with 
Coomassie brilliant blue. For Western blotting, after SDS-PAGE, sam- 
ples were electro-transferred, overnight at 40 mA to HighBond-C extra 
nitrocellulose membranes (Amersham). The membranes were saturated 
for 1 h with 3% gelatin in Tris/Tween-20 buffer solution, then chal- 
lenged with 1:500 rabbit antibodies against TIMP-2 [5] followed by 
1:1000 anti-rabbit immunoperoxidase-conjugated Ab (BioRad 170- 
6515) and HRP color development reagent (BioRad). 
2.8. Fluorescence spectroscopy 
Fluorescence measurements were carried out on a Perkin-Elmer flu- 
orescence spectrophotometer model LS-50 using a 0.5 ml internal vol- 
ume quartz cell with a 1-cm path length, thermostatted at 25°C. Sam- 
ples of rhTIMP-2 were prepared by dilution to 2 mM final concentra- 
tion in 100 mM NaCI, 10 mM sodium phosphate buffer (pH 7.5) and, 
when specified, 6 M guanidine hydrochloride (GdnHCI). After excita- 
tion of samples at 280 nm, fluorescence emission spectra were recorded 
from 300 to 450 nm. Four consecutive accumulations were averaged 
after subtraction of the corresponding base-line. 
2.9. Cell lines 
HT1080 human fibrosarcoma cells, and two variant clones from 
Lewis lung carcinoma, C87-LLC and BC215-LLC [25] were grown in 
Dulbecco's modified Eagle's medium (Flow) supplemented with 10% 
heat-inactivated f tal calf serum, 25/2g/ml gentamycin (Sigma), in 5% 
CO~ in air at 37°C. At 60-70% confluence, the cells were maintained 
in serum-free medium for additional 24 h, and the conditioned media 
were clarified and stored at -80°C until use. 
2.10. Gelatin zymography 
Gelatinolytic activity of all conditioned media was assayed by a 
modification of Clark's method [26], by electrophoresing unheated and 
unreduced samples in 1 mg/ml gelatin containing polyacrylamide g ls 
(BioRad). After removal of SDS by incubation in 2.5% (v/v) Triton 
X-100 for 30 min, the gels were incubated overnight at 37°C in 50 M 
Tris-HC1 (pH 7.4) containing 0.2 M NaC1 and 5 mM CaC12. The gels 
were stained for 30 min in 30% methanol/10% glacial acetic acid con- 
taining 0.5% (w/v) Coomassie brilliant blue R-250, and destained inthe 
same solution without dye. Gelatinolytic activity was evident as clear 
bands against a blue background. Their Mr were estimated by compar- 
ison with low-range pre-stained SDS-PAGE standards (BioRad). 
3. Results 
The gene for T IMP-2 was cloned as a fusion protein directly 
in the commercially available vector pRSETA, under the con- 
trol of T7 RNA polymerase-dependent promoter (Fig. 1). The 
recombinant vector pRSETIMP-2  coded for a 234 amino acid 
protein with a 34 amino acid tail at the TIMP-2 NH2-terminal 
(Fig. 1, below) with six consecutive histidine residues, which 
were effective in mediating its binding to an IMAC column [27]. 
This tail region had an enterokinase cleavage site DDDDK for 
eventual cleavage of the fusion protein. Five glycine residues 
made this extra domain flexible, as predicted by the FLEXPRO 
program (PCGENE Software, release 6.8 Intelligenetics) (data 
not shown). 
E. coli strain BL21 (DE3), containing the T7 RNA polym- 
erase gene under the control of the lac promoter, was trans- 
formed with plasmid pRSETIMP-2  and induced with IPTG. 
About  5% of total bacterial proteins were represented by a 
molecule of 28 kDa Mr, which is in agreement with the molec- 
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Fig. 1. Structure of expression vector coding fusion protein His-TIMP- 
2. Note direction of T7 DNA polymerase dependent promoter and 
relative position of histidine residues in fusion protein. Below: nucleo- 
tide sequence of His-TIMP2 recombinant fusion protein. 
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Fig. 2. Recombinant hTIMP-2 fusion protein expressed by E. coli and 
purified in IMAC column. Lane A = protein expressed by E. coli 
BL21 (DE3) transformed with plasmid pRSETIMP-2; lane B -- eluted 
proteins from IMAC column at pH 5.9; lane C = eluted proteins 
from IMAC column at pH 4.5; lane D -- refolded rhTIMP2 (reduced); 
lane E = refolded rhTIMP2 (unreduced); lane F--Western blot of 
rhTIMP2 with antibodies prepared against native human TIMP-2; lane 
G -- prestained molecular weight markers (BioRad). 
ular weight deduced from fusion protein DNA sequences 
(26,369 MW) (Fig. 2). The recombinant fusion protein, stored 
in E. coli as inclusion bodies, was directly solubilized by guani- 
dinium and purified on an IMAC column [27]. 
The purified rhTIMP-2 was judged to be 95% pure by SDS- 
PAGE in the presence offl-mercaptoethanol and in denaturing 
conditions. In non-reducing conditions, it revealed the presence 
of multimer bands, thus indicating uncorrected folding: this 
was also highlighted by protein precipitation and loss of biolog- 
ical activity when the urea was dialysed out. The rhTIMP-2 was 
recognised as a unique 30 kDa band by antibodies prepared 
against native human TIMP-2, as demonstrated by Western 
blotting of reduced rhTIMP-2 (Fig. 2). 
In order to obtain biologically active rhTIMP-2, we tried to 
refold rhTIMP-2 in the conditions used for rhTIMP-1 by 
Kohono et al. [11] in the presence of cystamine, although this 
procedure was reported as unsuccessful by Kleine et al. [13] for 
rhTIMP-1 and Cocuzzi et al. [12] for mouse TIMP-1. Kohono's 
procedure also failed to produce active human rTIMP-2 from 
E. coli (data not shown). A solid-phase refolding method was 
then optimised for TIMP-2, taking advantage of histidine bind- 
ing to Ni 2+ NTA resin. The procedure was carried on at a low 
protein/resin ratio (1 mg/ml resin), although this resin has a 
capacity of 10 mg protein per ml, as specified by the manufac- 
turer. This system was effective in recovering rhTIMP-2 which, 
although the protein was eluted out of the column at a high 
concentration (1 mg/ml), remained soluble. SDS-PAGE analy- 
sis of the refolded rhTIMP-2 revealed only the lower approxi- 
mately 26 kDa band, without a multimer ladder. The shift in 
Mr between reducing and non-reducing conditions fitted that 
observed for natural bovine TIMP-2, although the molecular 
weight of rhT1MP-2 was slightly higher, due to its extra tail. 
Additional information on the tridimensional structure of 
the refolded rhTIMP-2 was inferred from fluorescence spec- 
troscopy analysis• Fig. 3 shows that the/max of the peak relative 
fluorescence of native and denatured rhTIMP-2 (in the absence 
or presence of 6 M guanidinium) is red-shifted from 339 to 352 
nm. This is consistent with protein denaturation, in which the 
buried tryptophan residues are fully exposed to the solvent [28]. 
Moreover, the increase in fluorescence intensity of the dena- 
tured with respect to the native molecule indicates that the three 
tryptophan residues are quenched in the native structure [29]. 
The biological properties of recombinant hTIMP-2 were 
then checked by developing zymograms of tumour-secreted 
MMP-9 and MMP-2 gelatinases in buffer containing rhTIMP- 
2. As shown in Fig. 4, although rhTIMP-2 completely inhibited 
72 kDa gelatinase, both as a zymogen and in the activated form, 
it did not inhibit any other gelatinolytic activity. 
Binding to the protease and inhibitory activity involve two 
separate TIMP-2 domains, respectively at the COOH- and 
NHz-terminal domains of the inhibitor [30-32]• We therefore 
verified whether hTIMP-2 can bind other gelatinases. Addi- 
tion of rhTIMP-2 and ion-metal affinity resin to gelatinases 
containing media resulted in selective recovery of MMP-2 
alone, both as a zymogen and in its activated form (Fig. 4), with 
no other gelatinolytic activity. 
4. Discussion 
Recombinant technology usually has to use mammalian 
eukaryotic systems in order to produce active mammalian pro- 
teins. This is due mainly to the critical roles of both formation 
of correct disulphide bonds and glycosylation requirements. 
Since TIMP-2, unlike TIMP-1, is a non-glycosylated protein, 
we optimised its expression using a prokaryotic system, which 
is less expensive and time-consuming, paying attention to the 
refolding process. This was because TIMP-2 contains 12 cyste- 
ine residues which have the potential to originate numerous 
disulphide bridges, and at high protein concentrations both 
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Fig. 3. Fluorescence emission spectra of refolded rhTIMP-2 in 0 M 
(dotted line) and 6 M (solid line) GdnHC1 (2,ex = 280 nm). In both cases, 
were used the concentration f 10/zg/ml of rhTIMP-2. 
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Fig. 4. Gelatin zymography ofcells conditioned media. Lanes A and C = C87-LLC cells; lanes B and D = BC215-LLC cells; lanes C and D = were 
developed inpresence ofrhTIMP-2. In the right panel, specific affinity purification of MMP-2 from HT 1080 cells by IMAC-bound rhTIMP-2: lane 
E = media conditioned by HT1080 cells; lane F = fresh medium; lane G = enzymatic activity after affinity chromathography and elution with 
imidazole. 
intra- and inter-chain bonds may take place: in both cases, 
incorrect disulphide bonds may result. To avoid this problem, 
during refolding the protein must be diluted below 20 ¢tg/ml, 
thus avoiding aggregation, precipitation and loss of activity 
[13]. Nevertheless, because of the intrinsic chemical-physical 
characteristics of each protein, satisfactory activity ield is not 
routinely achieved. In order to avoid aggregation, one impor- 
tant requirement is to maintain physical separation between the 
molecules before their correct refolding. This has been now 
achieved by immobilizing rhTIMP-2 on an affinity chromato- 
graphic resin, through a flexible, especially engineered tail. This 
extension gives the steric freedom necessary to reach the native 
conformation, with the progressive removal of reducing and 
denaturing agents. Particular attention was paid to this step for 
correct refolding of the molecule: while in the above procedures 
the reducing and denaturing agents were directly diluted by 
water addition, we preferred to slow down the process by dial- 
ysis. 
Recombinant hTIMP-2 refolding was verified by a series of 
analyses. The higher Mr after SDS-PAGE of the molecule was 
indicative of compact folding; the change in fluorescence spec- 
troscopy, between ative and denatured states for buried and 
quenched tryptophan residues as for TIMP-1 [33], and the 
specificity of binding and inhibitory activity on MMP-2 eventu- 
ally ensured the correct ridimensional structure. While the tail 
binds to the physical support, the molecule is free to interact 
with target molecules. This solution may be very useful for 
specific sequestering of MMP-2 from any source for analytical 
or specific pharmacological purposes. The explanation of the 
restricted specificity of rhTIMP-2 compared with native inhib- 
itor awaits further investigation. But it is evident hat, on the 
one hand, the extra-specially designed NH~ tail does not impair 
rhTIMP-2 biological activity towards its elective counterpart. 
On the other hand, the domain where the tail was added has 
already revealed the fact that it may undergo modification 
without loss of biological activity. In fact, the first elucidation 
of the tridimensional structure of a mutated-deleted TIMP-2 
(corresponding to 1-127 amino acids of native protein) showed 
that the NH2 domain of DTIMP-2 is exposed to the solvent and 
does not seem to be essential for molecular interactions [33,34]. 
In conclusion, the method escribed here, which makes use 
of a prokaryotic system and of refolding controlled in the solid 
phase, has the potential to produce large amounts of active 
rhTIMP-2. The same procedure may turn out to be useful for 
a variety of other proteins in which correct disulphide bridging 
plays a critical role. 
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